Novartis AG (NYSE:NVS) 39th Annual J.P. Morgan Virtual Healthcare Conference Call January 11, 2021 11:40 AM ET
Company Participants
Vas Narasimham - Chief Executive Officer
Conference Call Participants
Richard Vosser - J.P. Morgan
Richard Vosser
Good afternoon. Welcome to the 39th J.P. Morgan Healthcare Conference. I'm Richard Voss, European Pharma Analyst at J.P. Morgan. It gives me great pleasure to introduce Vas Narasimham, CEO of Novartis, for this presentation.
Before I hand over to Vas, I'll remind you that if you would like to ask a question during the Q&A portion, then you can use the Q&A function at any time on the associated section of the website; and I'll read your question out at the appropriate time.
With that, I'd like to welcome Vas to the conference. Vas, over to you.
Vas Narasimham
Thank you, Richard. And thanks, everyone, for joining today. I'd like to give you an update on our progress on our strategy for Novartis, and give you some of the insights on how we progressed over the recent years on delivering both, on our operational performance, but more importantly, on our longer term strategy to deliver consistent growth, consistent innovation and be a leading medicines company continuing to reimagine medicine.
If you move to Slide 3, we're on a journey to transform our company. We set out a clear strategy in 2018 to focus our company and capital, accelerate certain geographies and strengthen our core therapeutic areas alongside five strategic priorities, which I'll walk you through a little bit later in the presentation. When you look at the recent years, we've been successful to-date in making progress and transforming the company; we are a 100% focused medicines company today, we're achieving record high engagement scores in terms of our culture, we've developed a leading pipeline and that consistency in our pipeline, I think, really shows that we have
- Read more current NVS analysis and news
- View all earnings call transcripts